MODIFICATION
A -- Development of Dosage Forms and Delivery Systems for Antitumor Agents
- Notice Date
- 12/6/2001
- Notice Type
- Modification
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Room 604, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- N01-CM-27004-19
- Response Due
- 1/21/2002
- Archive Date
- 2/5/2002
- Point of Contact
- Diane Stalder, Contract Specialist, Phone (301) 435-3822, Fax (301) 402-6699 - MaryAnne Golling, Contracting Officer, Phone (301) 435-3819, Fax (301) 402-6699
- E-Mail Address
-
ds88b@nih.gov, mg345x@nih.gov
- Description
- Amendment 01 to SOL N01-CM-27004-19 changes the release date of the SOL from on or about November 29, 2001 to December 06, 2001 and the response date from January 07, 2002 to January 21, 2002. The Pharmaceutical Resources Branch of the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (PRB/DTP/DCTD/NCI) is seeking contractors to develop acceptable dosage forms for compounds to be subsequently evaluated in cancer patients. NCI will select and provide the compounds to be studied. In addition to solubility studies, the projects may require analytical work, particularly the development of a stability-indicating assay to monitor the integrity of the parent compound during the formulation studies. These investigations will be directed toward a pharmaceutical dosage form that will meet certain solubility and stability targets determined by the Government. Data will be submitted to the Project Officer primarily in the form of progress reports but additional reports may be required. The Contractor will be required to maintain laboratory notebooks containing raw data at the contract site. The data will remain at the contract site but copies may be requested at the discretion of the Government. The Contractors may be assigned compounds covered by a discreet agreement. Therefore, the contract will contain the current confidentiality clause in accordance with HHSAR 352-224-70. The Principal Investigator on this project should possess a Ph.D. in Pharmaceutics or Medicinal Chemistry and should also have at least three years experience in the development of injectable formulations. It is anticipated that three (3) cost-reimbursement term (level of effort) type contracts will be awarded for five (5) years. The proposed contract project represents a re-competition of the following contracts: NO1-CM-77109 (University of Arizona), NO1-CM-77017 (University of Kansas), and NO1-CM-77108 (University of Utah). All responsible offerors will be considered. The solicitation is scheduled for electronic release on or about December 06, 2001. The proposals will be due approximately 30 days following the actual date of RFP issuance. The RFP may be accessed through the Research Contracts Branch Home Page by using the following Internet address: http://rcb.nci.nih.gov/ It's the offeror's responsibility to monitor the above Internet site for the release of this solicitation and amendments, if any. POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND AMENDMENTS. Point of contact: Diane Stalder, Contract Specialist at e-mail: ds88b@nih.gov; FAX: 301-402-6699; Telephone: 301-435-3822. No collect calls will be accepted.
- Record
- SN20011206/00001192-011207190740 (fbodaily.com)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |